Robert Stott

PHILADELPHIA — None of the top 25 insurers in the United States offer explicit policy coverage for primary or revisional endoscopic bariatric therapies, according to data presented at the ACG Annual Scientific Meeting.“While lifestyle interventions have yielded transient and modest effect sizes, surgical interventions [for obesity] have produced the largest effects; however, surgeries

PHILADELPHIA — Zymfentra as monotherapy was no more effective when combined with immunosuppressants for maintenance therapy in patients with Crohn’s disease or ulcerative colitis, according to post-hoc analysis presented here. “[Zymfentra] is a subcutaneous form of infliximab, which has shown superior efficacy over placebo for maintenance therapy up to 1 year in patients

PHILADELPHIA — Iqirvo demonstrated significant biochemical response and alkaline phosphatase normalization in patients with both early- and advanced-stage primary biliary cholangitis, according to late-breaking data presented here. “Elafibranor — a peroxisome proliferator-activated receptor agonist — has demonstrated significant biochemical response in 51% vs. 4% of

PHILADELPHIA — A “high prevalence” of extremity repetitive use injury symptoms were reported among endoscopists, which negatively affected performance, according to a presenter at the ACG Annual Scientific Meeting. “A [2015] ASGE survey reported that 78% of endoscopists had an extremity repetitive use injury, or ERI,” Daryl Ramai, MD, MPH, MSc, an advanced endoscopy

PHILADELPHIA — On-demand vonoprazan effectively reduced heartburn symptom severity in patients with nonerosive reflux disease within 1 hour of treatment, according to data presented at the ACG Annual Scientific Meeting. “On-demand treatment for nonerosive reflux disease is suitable primarily for patients who do not have a high frequency of heartburn,” Ronnie Fass, MD, MACG,

Eight years ago, Ocaliva was a prospective lifesaver for patients with primary biliary cholangitis who failed to adequately respond to first-line ursodeoxycholic acid. However, the once-promising drug now finds itself struggling to deliver.

In a Healio video exclusive, Edward V. Loftus Jr., MD, discusses the looming threat of gastroenterology workforce shortage, alongside insights from a roundtable of ACG presidents on how we might still avoid it. “I think we all feel it on some level,” Loftus said. “By some estimates, there is projected to be a shortage of over 1,000 gastroenterologists over the next few years. I

The AGA reported that it could not issue a recommendation for or against the use of computer-aided detection in colonoscopy due to “very low certainty of evidence” and “the close tradeoff between the desirable and undesirable effects.”The association cautioned that, although AI is credited with increased detection of low-risk colorectal polyps during colonoscopy, there

The FDA issued a complete response letter to Genentech indicating it cannot approve the company’s biologic license application seeking approval for glofitamab-gxbm as a treatment for relapsed or refractory diffuse large B-cell lymphoma.In its letter, the agency cited that data from the phase 3 STARGLO study failed to provide sufficient evidence to support glofitamab-gxbm (Columvi) as

A virtual multispecialty cancer support clinic intends to “connect the dots” to match patients with specialists within 3 days to help manage side effects of cancer treatment, including drug reactions and treatment-emergent adverse events.“About 85% of cancer patients receive their cancer treatments in community cancer centers where access to specialists like endocrinologists,